GRAIL said demand for its Galleri multi-cancer early detection test has continued to grow, despite recent headlines related to its NHS study. The update came from the company's CFO, Aaron, during a Bank of America event. The note is supportive for the demand outlook, but it contains no new financial metrics or guidance.
GRAIL said demand for its Galleri multi-cancer early detection test has continued to grow, despite recent headlines related to its NHS study. The update came from the company's CFO, Aaron, during a Bank of America event. The note is supportive for the demand outlook, but it contains no new financial metrics or guidance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
